GenRx Midazolam midazolam 15mg/3mL solution for injection ampoule

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

midazolam, Quantity: 15 mg

Commercializzato da:

Arrotex Pharmaceuticals Pty Ltd

INN (Nome Internazionale):

Midazolam

Forma farmaceutica:

Injection, solution

Composizione:

Excipient Ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide

Via di somministrazione:

Intravenous, Intramuscular

Confezione:

5 ampoules

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

IV as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic. IV for induction of anaesthesia, preliminary to administration of other anaesthetic agents. With the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. IV for sedation in intensive care units; intermittent administration or continuous infusion. IM for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Dettagli prodotto:

Visual Identification: A clear colourless to pale yellow solution.; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2014-10-30